yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q34344198-39F21AC3-7186-4228-9B39-D835CC373BEA
Q34344198-39F21AC3-7186-4228-9B39-D835CC373BEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34344198-39F21AC3-7186-4228-9B39-D835CC373BEA
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
P2860
Q34344198-39F21AC3-7186-4228-9B39-D835CC373BEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34344198-39F21AC3-7186-4228-9B39-D835CC373BEA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4aa832b54a25d5065469c62f6fa321bf2c3c010c
P2860
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial